Sosei Heptares expands its UK R&D operations to a second site within Granta Park, Cambridge


TOKYO, Japan and CAMBRIDGE, UK, May 26, 2022 (GLOBE NEWSWIRE) — Sosei Group Company (“the Company”; TSE: 4565), a global leader in the design and development of structure-based drugs (SBDDs) focused on G-protein-coupled receptors (GPCRs), today announces that it has expanded its UK R&D operations at a second site within Granta Park, Cambridge, at the Cori Building, previously occupied by Cancer Research UK.

The need for additional R&D space is driven by the Company’s strategy to become a multi-program, early-clinical-stage company while continuing to be a discovery and development partner of choice for leading biopharmaceutical companies. As part of this strategy, Sosei Heptares continues to invest in enhancing its proprietary GPCR-focused discovery platform and expanding its R&D capability to support the advancement of its internal pipeline and programs. in partnership. The existing facility, the Steinmetz building, will soon be remodeled to convert it exclusively into laboratory space.

The new facilities in the Cori building will house Sosei Heptares’ expanded translational medicine team. This team is focused on taking an enterprise-like approach to the abundance of new discovery candidates generated by the Company’s discovery platform. The objective being to accelerate the prioritization and rapid progression of programs through phase 1b/2a trials to establish clinical proof of concept; a key value inflection point to support future development and partnership opportunities.

Chris Cargill, President and CEO of Sosei Heptarescommented : “This expansion of our R&D capability reflects the significant growth and development the Company has experienced over the past few years, thanks to the excellent work we are doing with our partners and collaborators. We now employ almost 200 expert R&D team members in Cambridge, which were just 130 when we first moved to Granta Park in 2018. Our establishment as a leading biopharmaceutical company in the region of Cambridge has benefited us greatly, allowing us to tap into the rich pool of R&D talent in the region. We are excited about the future of the company and are equipped and motivated to capitalize on the enormous potential of our GPCR-driven platform to deliver much-needed medicines to patients as quickly and efficiently as possible.

About Sosei Heptares
We are an international biopharmaceutical group focused on the discovery and early development of new drugs based on our patented GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of new drugs in multiple therapeutic areas, including neurology, immunology, gastroenterology and inflammatory diseases.

We have established partnerships with some of the world’s largest pharmaceutical companies and several emerging technology companies, including AbbVie, AstraZeneca, Genentech (Roche), GSK, Kallyope, Neurocrine Biosciences, Novartis, Pfizer, Takeda and Verily. Sosei Heptares is headquartered in Tokyo, Japan, with corporate and R&D facilities in Cambridge, UK.

“Sosei Heptares” is the trademark and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are registered trademarks of Sosei Group companies.

For more information, please visit
LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | Youtube: @soseiheptaresco


Sosei Heptares – Media and Investor Relations
Hironoshin Nomura, CFO
Shinichiro Nishishita, Vice President of Investor Relations, Head of Regulatory Disclosures
Candelle Chong, Senior Vice President of Investor Relations and Corporate Strategy

Japan: +81 (0)3 5210 3399 | UK: +44 (0)1223 949390 |

MEDiSTRAVA Consulting (for international media)
Mark Swallow, Frazer Hall, Eleanor Perkin
+44 (0)203 928 6900 |

Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. A variety of risks could cause Sosei Group Corporation’s actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programs; the inability to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; reliance on strategic alliance partners to develop and market products and services; difficulties or delays in obtaining regulatory approvals to commercialize products and services resulting from development efforts; the requirement for substantial funding to conduct research and development activities and to expand commercialization activities; and product initiatives by competitors. Due to these factors, potential investors are cautioned not to rely on forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

main logo


Comments are closed.